Cov19 FluoBolt-™ DUO SN


Summary and Explanation
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a recently identified coronavirus strain responsible for the Coronavirus Disease 2019 (COVID-19) and pandemic. SARS-CoV-2 emerged in China in December 2019 and is transmitted mainly through droplets and surface contact routes. Symptoms can include signs and symptoms of acute respiratory illness, such as fever, cough, shortness of breath, but the infection can also be asymptomatic. The virus infects human cells through interaction with angiotensin converting enzyme 2 (ACE2) on the surface of respiratory cells and spike (S) protein on the outer envelope of the virion particle, specifically with its receptor binding domain (RBD). The Spike (S) and nucleocapsid protein (NC), are the main immunogens of SARS-CoV-2. Antibodies against the RBD of the S protein are considered to have neutralizing activity as they can block the interaction with the ACE2 receptor, thereby blocking cellular infiltration. The emergence of more and more immune-evasive and/or more infectious variants and waning immunity after infection or vaccination generates an ongoing need for SARS-CoV-2 antibody measurements.

Therefore, to complement our SARS-Cov-2 serology portfolio, we decided to use our FluoBolt™-Technology to develop a

DUAL PLATE QUANTITATIVE ANTIBODY MEF-FIA FOR THE DETECTION OF ANTIBODIES AGAINST THE NUCLEOCAPSID AND THE S1-RECEPTOR BINDING DOMAIN OF HUMAN SARS-COV-2 VIRUS (“Cov19 FluoBoltTM-DUO SN” Art. Nr. FIA-1708-C5)

In contrast to our “Cov19 FluoBoltTM-DAT” (Art. Nr. FIA-1707-FC5) this new assay is not epitope specific and therefore allows quantitative measurement of a broad spectrum of antibodies against the S1RBD and the NC antigen of SARS-CoV-2 on separate plates.

This results in an excellent clinical agreement and correlation to many other assays used in SARS-Cov-2 serology:
Tabelle s1-nc

Therefore, the “Cov19 FluoBoltTM-DUO SN” is your best choice for comparative assay studies.

Principle of the assay:

Anti-S1RBD and anti-NC antibodies present in serum or plasma samples from patients bind to NC-protein and the S1RBD coated onto separate metal enhanced fluorescence microtiter plates (MEF-MTP). Detection of bound antibodies is accomplished with Cy5-labelled anti-human antibodies. Calibrators with a given amount of anti-S1RBD and anti-NC antibodies are used to construct calibration curves to quantify the antibody concentration of an unknown sample.

MEF-FIA for SARS-COV.2-S1
MEF-FIA for SARS-COV.2-NC

Literature

Antibody response to SARS-CoV-2 infection in humans: A systematic review. Post N et al., PLoS One. 2020 Dec 31;15(12):e0244126.
The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Smits VAJ et al., Biochem Biophys Res Commun. 2021 Mar 5;543:45-49
Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals. Brochot E. et al., Front Microbiol. 2020 Oct 19;11:584251
The SARS-CoV-2 spike protein: balancing stability and infectivity. Berger I, Schaffitzel C. Cell Res. 2020 Dec;30(12):1059-1060. doi: 10.1038/s41422-020-00430-4. PMID: 33139926; PMCID: PMC7604330
Human neutralizing antibodies elicited by SARS-CoV-2 infection. Ju B, Zhang Q, Ge J, et al. Nature. 2020 Aug;584(7819):115-119. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26. PMID: 32454513.

Application of SARS-CoV-2 Serology to Address Public Health Priorities. Sherman AC et al., Front Public Health. 2021 Nov 23;9:744535.
Silent SARS-CoV-2 Infections, Waning Immunity, Serology Testing, and COVID-19 Vaccination: A Perspective. Narasimhan M et al., Front Immunol. 2021 Sep 21;12:730404.

Remote Fingerstick Blood Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Testing.
Garcia-Beltran WF et al., Arch Pathol Lab Med. 2021 Apr 1;145(4):415-418.

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. Matta J et al.,JAMA Intern Med. 2022 Jan 1;182(1):19-25

Order now !

Order Nr. FIA-1708-FC5